Bioventus (BVS) Operating Expenses (2020 - 2026)

Bioventus' Operating Expenses history runs 7 years deep, the most recent figure standing at $81.2 million for Q1 2026.

• Quarterly Operating Expenses rose 6.19% year-over-year to $81.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330.9 million (down 6.22% YoY) and the FY2025 annual result came in at $328.4 million, down 8.2% from the prior year.
• Operating Expenses was $81.2 million for Q1 2026 at Bioventus, down from $85.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $100.9 million in Q2 2024 and bottomed at $72.8 million in Q3 2023.
• A 5-year average of $85.1 million and a median of $84.1 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 162.76% — and 2023, when it dropped 18.69%.
• Bioventus' Operating Expenses stood at $88.0 million in 2022, then retreated by 7.33% to $81.5 million in 2023, then rose by 10.48% to $90.1 million in 2024, then retreated by 4.8% to $85.8 million in 2025, then dropped by 5.27% to $81.2 million in 2026.
• Business Quant data shows BVS's Operating Expenses at $81.2 million in Q1 2026, $85.8 million in Q4 2025, and $81.6 million in Q3 2025.